MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Status:
Active, not recruiting
Trial end date:
2022-07-13
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456
and EU approved RoActemra® in participants with moderately to severely active rheumatoid
arthritis.
Participants will be randomized at the beginning of the Core Treatment Period (Baseline to
Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the
beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received
RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to
receive MSB11456 QW.